Liza Takiya

1.7k total citations
47 papers, 888 citations indexed

About

Liza Takiya is a scholar working on Rheumatology, Hematology and Dermatology. According to data from OpenAlex, Liza Takiya has authored 47 papers receiving a total of 888 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Rheumatology, 13 papers in Hematology and 12 papers in Dermatology. Recurrent topics in Liza Takiya's work include Rheumatoid Arthritis Research and Therapies (20 papers), Autoimmune and Inflammatory Disorders Research (13 papers) and Dermatology and Skin Diseases (11 papers). Liza Takiya is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Autoimmune and Inflammatory Disorders Research (13 papers) and Dermatology and Skin Diseases (11 papers). Liza Takiya collaborates with scholars based in United States, Australia and Germany. Liza Takiya's co-authors include Rebecca S. Finley, Andrew M. Peterson, Roy Fleischmann, Jeffrey R. Curtis, Eustratios Bananis, Ronald van Vollenhoven, Lisy Wang, Pinaki Biswas, J. Wollenhaupt and Thomas V. Jones and has published in prestigious journals such as PEDIATRICS, Journal of Allergy and Clinical Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Liza Takiya

44 papers receiving 844 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Liza Takiya United States	15	282	267	148	137	137	47	888
Douglas Berger United States	13	102 0.4×	177 0.7×	81 0.5×	4 0.0×	31 0.2×	26	1.0k
Jason Yeaw United States	12	225 0.8×	203 0.8×	103 0.7×	4 0.0×	39 0.3×	37	847
Amye Leong United States	17	28 0.1×	411 1.5×	12 0.1×	15 0.1×	206 1.5×	34	799
Shonda A. Foster United States	18	28 0.1×	197 0.7×	24 0.2×	41 0.3×	17 0.1×	41	782
Bruno Émond United States	15	44 0.2×	19 0.1×	34 0.2×	28 0.2×	81 0.6×	94	788
K Malottki United Kingdom	11	11 0.0×	166 0.6×	10 0.1×	99 0.7×	77 0.6×	17	725
Safiya Abouzaid United States	16	113 0.4×	18 0.1×	202 1.4×	8 0.1×	405 3.0×	41	971
Evrydiki Kravvariti Greece	14	15 0.1×	289 1.1×	25 0.2×	10 0.1×	68 0.5×	44	608
Pongthorn Narongroeknawin Thailand	16	30 0.1×	322 1.2×	18 0.1×	17 0.1×	91 0.7×	42	617
Hilary H. Colwell United States	17	6 0.0×	151 0.6×	14 0.1×	71 0.5×	75 0.5×	39	848

Countries citing papers authored by Liza Takiya

Since Specialization

Citations

This map shows the geographic impact of Liza Takiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liza Takiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liza Takiya more than expected).

Fields of papers citing papers by Liza Takiya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liza Takiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liza Takiya. The network helps show where Liza Takiya may publish in the future.

Co-authorship network of co-authors of Liza Takiya

This figure shows the co-authorship network connecting the top 25 collaborators of Liza Takiya. A scholar is included among the top collaborators of Liza Takiya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liza Takiya. Liza Takiya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Piliang, Melissa, Charles Lynde, Brett King, et al.. (2024). Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial. Journal of the American Academy of Dermatology. 92(2). 276–284. 5 indexed citations

Mesinkovska, Natasha Atanaskova, Brett King, Xingqi Zhang, et al.. (2024). Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. The Journal of Dermatology. 51(11). 1414–1424. 2 indexed citations

Senna, Maryanne M., Seth Forman, Lindsey A. Bordone, et al.. (2023). 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study. Journal of the American Academy of Dermatology. 89(3). AB221–AB221. 1 indexed citations

King, Brett, Edmund J. Pezalla, Helen Tran, et al.. (2023). Overview of alopecia areata for managed care and payer stakeholders in the United States. Journal of Managed Care & Specialty Pharmacy. 29(7). 848–856. 2 indexed citations

Piliang, Melissa, Charles Lynde, Brett King, et al.. (2023). 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study. Journal of the American Academy of Dermatology. 89(3). AB91–AB91. 1 indexed citations

Zeichner, Joshua, Steven R. Feldman, Rebecca J. Crawford, et al.. (2021). 26652 Patient and caregiver perspectives on treatment attributes for atopic dermatitis. Journal of the American Academy of Dermatology. 85(3). AB111–AB111.

Su, John, Lynda Spelman, Lawrence F. Eichenfield, et al.. (2021). Efficacy And Safety Of Crisaborole In Patients Aged 3 Months To 17 Years With Mild-To-Moderate Atopic Dermatitis. PEDIATRICS. 147(3_MeetingAbstract). 302–303.

Kivitz, Alan, Oliver FitzGerald, Peter Nash, et al.. (2021). Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. Clinical Rheumatology. 41(2). 499–511. 8 indexed citations

Schlessinger, Joel, Richard Gower, John Su, et al.. (2020). Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). American Journal of Clinical Dermatology. 21(2). 275–284. 66 indexed citations

10.

Spergel, Jonathan M., Michael S. Blaiss, Peter Lio, et al.. (2020). P500 EFFICACY OF CRISABOROLE IN PATIENTS WITH MILD-TO-MODERATE ATOPIC DERMATITIS WITH AND WITHOUT COMORBID ALLERGIC RHINITIS. Annals of Allergy Asthma & Immunology. 125(5). S46–S46. 1 indexed citations

11.

Reed, George, Robert A. Gerber, Ying Shan, et al.. (2019). Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis. Rheumatology and Therapy. 6(4). 573–586. 34 indexed citations

12.

Calabrese, Leonard H., Carlos Abud‐Mendoza, Stephen Lindsey, et al.. (2019). Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care & Research. 72(3). 353–359. 19 indexed citations

13.

Fleischmann, Roy, J. Wollenhaupt, S. Cohen, et al.. (2018). SAT0247 Impact of glucocorticoids on efficacy and safety of tofacitinib with and without methotrexate and adalimumab with methotrexate for rheumatoid arthritis: results from a phase 3b/4 randomised trial. Annals of the Rheumatic Diseases. 77. 985–986. 4 indexed citations

14.

Fleischmann, Roy, J. Wollenhaupt, Stanley Cohen, et al.. (2018). Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatology and Therapy. 5(1). 203–214. 14 indexed citations

15.

Kivitz, Alan, Stanley Cohen, Edward Keystone, et al.. (2018). A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Seminars in Arthritis and Rheumatism. 48(3). 406–415. 33 indexed citations

16.

Strand, Vibeke, Eun Bong Lee, Yusuf Yazıcı, et al.. (2018). Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clinical Rheumatology. 37(8). 2043–2053. 7 indexed citations

17.

Genovese, Mark C., Ronald van Vollenhoven, Bethanie Wilkinson, et al.. (2016). Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Research & Therapy. 18(1). 145–145. 15 indexed citations

18.

Takiya, Liza, et al.. (2006). Safety and Efficacy of Eletriptan in the Treatment of Acute Migraine. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(1). 115–128. 16 indexed citations

19.

Peterson, Andrew M., Liza Takiya, & Rebecca S. Finley. (2003). Meta‐Analysis of Interventions To Improve Drug Adherence in Patients with Hyperlipidemia. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(1). 80–87. 21 indexed citations

20.

Takiya, Liza, et al.. (2002). Therapeutic options for the management of type 2 diabetes mellitus.. PubMed. 8(11). 1009–23; quiz 1024. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact